Q4 Aktie
WKN DE: A3DLU3 / ISIN: CA74738R1047
|
26.02.2026 20:38:52
|
Lantheus (LNTH) Q4 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, Feb. 26, 2026 at 8 a.m. ETLantheus (NASDAQ:LNTH) emphasized a strategic pivot to PET radiodiagnostics, highlighted by the divestiture of its SPECT business on Jan. 1, 2026, and the acquisitions of Neuraceq and OCTEVY, with four near-term FDA approval catalysts identified. Management stated that 2026 will be a year of investment in commercialization infrastructure, with the majority of revenue growth acceleration and portfolio diversification expected in 2027 following late-year product launches. The company will also optimize its cost base and reassess its radiotherapeutic pipeline for value-maximizing externalization or partnerships, indicating a restrained near-term M&A approach.Continue readingWeiter zum vollständigen Artikel bei MotleyFool
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Q4 Inc Registered Shs Unitary
| Keine Nachrichten verfügbar. |
Analysen zu Lantheus Holdings Inc
Aktien in diesem Artikel
| Lantheus Holdings Inc | 64,06 | 0,47% |
|